New drug shows promise in reversing kidney damage from rare autoimmune disease

Avacopan, a novel treatment for ANCA-associated vasculitis, helped patients with severely compromised kidney function recover filtering capacity in a major clinical trial. The finding could expand treatment options for a rare but serious condition and inform how drugmakers approach kidney disease more broadly.

Originaltitel: Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan